Medexus Pharmaceuticals Inc.
MEDXF
$2.00
$0.084.06%
OTC PK
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 0.51% | -0.56% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.51% | -0.56% | |||
| Cost of Revenue | 1.34% | -14.83% | |||
| Gross Profit | 0.07% | 9.05% | |||
| SG&A Expenses | -2.05% | -0.07% | |||
| Depreciation & Amortization | 0.08% | -0.41% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.85% | -5.11% | |||
| Operating Income | 94.47% | 393.10% | |||
| Income Before Tax | -153.17% | 181.03% | |||
| Income Tax Expenses | -112.12% | 148.06% | |||
| Earnings from Continuing Operations | -161.05% | 193.31% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -161.05% | 193.31% | |||
| EBIT | 94.47% | 393.10% | |||
| EBITDA | 24.57% | 55.78% | |||
| EPS Basic | -161.25% | 185.56% | |||
| Normalized Basic EPS | -300.00% | -80.00% | |||
| EPS Diluted | -162.50% | 185.56% | |||
| Normalized Diluted EPS | -300.00% | -80.00% | |||
| Average Basic Shares Outstanding | 0.09% | 8.97% | |||
| Average Diluted Shares Outstanding | 0.09% | 8.97% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||